Interaction between valproic acid and carbapenems: Case series and literature review  by Lee, Ming-Chia et al.
at SciVerse ScienceDirect
Tzu Chi Medical Journal 24 (2012) 80e84Contents lists availableTzu Chi Medical Journal
journal homepage: www.tzuchimedjnl .comCase Report
Interaction between valproic acid and carbapenems: Case series and literature
review
Ming-Chia Lee a, Yi-Hsuan Sun a, Chih-Hsin Lee b,c,d, An-Jan Wu a, Ta-Wei Wu a,*
aDepartment of Pharmacy, Buddhist Tzu Chi General Hospital, Taipei Branch, New Taipei City, Taiwan
bGraduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan
cDepartment of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei Branch, New Taipei City, Taiwan
d School of Medicine, Tzu Chi University, Hualien, Taiwana r t i c l e i n f o
Article history:
Received 11 November 2011
Received in revised form
5 December 2011




Valproic acidConﬂict of interest: none.
* Corresponding author. Department of Pharmacy
Hospital, Taipei Branch, 289, Jianguo Road, New Taip
6628 9779x8900; fax: þ886 2 6628 5288.
E-mail address: p8561825@yahoo.com.tw (T.-W. W
1016-3190/$ e see front matter Copyright  2012, Bu
doi:10.1016/j.tcmj.2012.02.008a b s t r a c t
Several case reports and retrospective studies have indicated that carbapenems decrease the serum
concentration of valproic acid (VPA), thus decreasing its therapeutic activity. This study evaluates
a potential drug interaction between VPA and carbapenems in a regional hospital. This retrospective
observational study was performed over a 14-month period from January 2010 to February 2011. Patients
concurrently receiving VPA and carbapenems who had at least two serially measured concentrations of
serum VPA prior to, during, or after this combined treatment were included. Patients whose serum
samples for VPA were drawn within 2 hours after VPA administration who had severe liver impairment
or who received other drugs that could potentially interact with VPA were excluded from the study. The
serum levels and therapeutic activities of VPA during coadministration of carbapenems were recorded
and evaluated. Nine VPA-treated patients were identiﬁed who concomitantly received meropenem
(n ¼ 5), ertapenem (n ¼ 3), or imipenem (n ¼ 1). Mean serum VPA trough levels during combined
treatment decreased by 76.3% (from 55.6  22.9 mg/mL to 13.2  6.1 mg/mL) from values before carba-
penem treatment. However, only one patient experienced seizures after a combination of VPA and
carbapenems. The coadministration of VPA and carbapenems resulted in decreased trough concentra-
tions of VPA. Clinicians should be aware of this potential interaction and closely monitor serum VPA
levels and possible failure to control seizures with the concomitant use of carbapenems.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Valproic acid (VPA) is widely used in the treatment of epileptic
seizures and status epilepticus. A VPA serum concentration of
50e150 mg/L has been reported to be acceptable for therapeutic
effects [1]. Several case reports and retrospective studies have
reported an interaction between VPA and carbapenem antibiotics
[2e19] leading to a rapid decline in the serum VPA concentration
and, in some cases, myoclonia or seizures (Table 1) [2e15,18,19]. We
report a possible interaction between VPA and carbapenem anti-
biotics resulting in reduced serum VPA concentrations in nine
patients., Buddhist Tzu Chi General
ei City, Taiwan. Tel.: þ886 2
u).
ddhist Compassion Relief Tzu Chi2. Case report
We performed this retrospective observational study over
a 14-month period from January 2010 to February 2011 to assess
potential drug interactions between VPA and carbapenem antibi-
otics including meropenem, ertapenem, and imipenem. Patients
concurrently receiving VPA and carbapenems who had at least two
serially measured concentrations of serum VPA prior to, during, or
after this combined treatment were included. Patients whose serum
samples for VPA were drawn within 2 hours after VPA administra-
tion, who had severe liver impairment, or who received other drugs
that could potentially interact with VPA were excluded from this
study. Drugs that could potentially interact with VPA included
phenobarbital, phenytoin, carbamazepine, topiramate, acyclovir,
rifampin, ritonavir, ethosuximide, isoniazide, and felbamate. The
serum levels and therapeutic activities of VPA during coadminis-
tration of carbapenems were recorded and evaluated. The average
drop in serum VPA levels before and during coadministration of
carbapenems was tested using the Wilcoxon signed-rank test.Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Overview of published case reports.
References Age, (year) Daily VPA dose Type of carbapenem Effect on VPA concentration, (%) Seizure attack after combination
Nagai (1997) [2] 10 8.3 mg/kg tid panipenem Y93.5 yes, on day 13
8 500 mg panipenem Y95 no
De Turck (1998) [3] 65 1200 mg meropenem Y63.6 yes, on day 2
57 unknown meropenem Y88.6 no
Yamagata (1998) [4] 3 35 mg/kg/day panipenem Y65 yes, on day 3
22 32 mg/kg/day panipenem Y76 yes, on day 2
4 25 mg/kg/day panipenem Y58.5 no
Llinares (2003) [5] 28 1600 mg imipenem Y70 no
71 1500 mg meropenem Y75 yes, on day 9
24 1600 mg meropenem unknown no
Nacarkucuk (2004) [6] 14 50 mg/kg/day meropenem Y47.5 no
7 month 75 mg/kg/day meropenem Y75.5 no
14 month 75 mg/kg/day meropenem Y84.7 no
Clause (2005) [7] 30 3600 mg/day meropenem Y72 no
77 24 mg/kg/day meropenem unknown no
Coves-Orts (2005) [8] 21 1000 mg meropenem Y20.1 yes, on day 2
Santucci (2005) [9] 9.5 600 mg meropenem Y64 yes, on day 5
Cabanes (2006) [10] 80 1100 mg ertapenem Y49 no
Fudio (2006) [11] 55 1500 mg meropenem Y85 yes, on day 5
Spriet (2007) [12] 60 32 mg/kg/day meropenem Y68 no
54 28 mg/kg/day meropenem Y56 no
Lunde (2007) [13] 41 2000 mg/day ertapenem Y84.7 yes, on day 7
Lee (2007) [14] 57 900 mg/day panipenem Y74 yes, on day 9
56 900 mg/day meropenem Y91 no
65 1200 mg/day Imipenem Y70 no
79 1200 mg/day meropenem Y88 no
80 1080 mg/day meropenem Y88 no
51 1000 mg/day imipenem Y29 no
28 1200 mg/day imipenem Y34 no
1200 mg/day meropenem Y89 no
Gu (2009) [15] 85 800 mg meropenem Y72 no
Y74 yes, on day 10
Liao (2010) [18] 47 24 mg/kg/day ertapenem unknown no
72 25 mg/kg/day ertapenem Y32.1 yes, on day 7
Hellwig (2011) [19] 54 750 mg doripenem Y62 unknown
54 3750 mg doripenem Y69 unknown
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received VPA and carbapenem antibiotics including meropenem,
ertapenem, and imipenem were identiﬁed by a computerized ﬁle
system. Patients who did not have measurements of the serum
VPA concentration before the combined treatment (n ¼ 56), and
those who were receiving medications which could potentially
interact with VPA (n ¼ 15) were excluded. Only nine VPA-treated
patients who concomitantly received meropenem (n ¼ 5), erta-
penem (n ¼ 3), or imipenem (n ¼ 1) met the inclusion criteria
(Table 2). The ratio of men to women was 4:5, and the mean age
was 73.0  14.6 years. VPA was given for treatment of seizures
(n ¼ 8) and bipolar disorder (n ¼ 1). The mean daily VPA dose was
1.04  0.34 g. Fig. 1 summarizes the data on the mean trough
VPA concentrations of all patients before, during, and after dis-
continuing of carbapenems. The mean serum concentration of
VPA was 55.6  22.9 mg/mL (range 29.8e98.6 mg/mL) beforeTable 2
Demographic characteristics of our nine patients.
Patient Age, y Sex Daily VPA Dose Type of Carbapenem Duration of c
1 88 F 800 meropenem 6
2 87 M 1600 meropenem 6
3 69 M 1200 meropenem 3
4 54 M 1000 meropenem 9
5 75 F 1200 meropenem 8
6 47 F 1200 ertapenem 7
7 85 M 1200 ertapenem 13
8 82 F 800 ertapenem 12
9 70 F 400 imipenem 4
VPA ¼ Valproic acid.carbapenem treatment and 13.2  6.1 mg/mL (range <3e22.41 mg/
mL) during carbapenem treatment, representing an average drop
of 76.3% (p ¼ 0.008). However, only one patient experienced
seizures during or after the combined treatment. During VPA and
carbapenem treatment, one patient received 0.8 g as an emer-
gency loading dose. The VPA doses for two patients were adjusted
from 1.2 g to 1.8 g and 0.8 g to 1.2 g; however, this did not increase
their serum VPA concentrations. The serum VPA concentration was
obtained on the ﬁrst day of combined treatment in one patient,
and 4 to 9 days after the beginning of treatment in the other
patients. Unfortunately, serum VPA concentrations were not
obtained for all patients after discontinuation of carbapenems.
After discontinuing carbapenem treatment, the serum VPA
concentration increased from 11.6 mg/dL to 62.1 mg/dL on day 8 in
one patient, and from 18.2 mg/dL to 49 mg/dL on day 12 in another
patient.oncurrent use, days Effect on VPA concentration, % Outcome
Y79 No acute seizure
Y68 No acute seizure
Y88 Seizure on day 4
Y90 No acute seizure
Y67 No acute seizure
Y81 No acute seizure
Y64 No acute seizure
Y85 No acute seizure
Y49 Bipolar well-controlled
Fig. 1. The serum valproic acid (VPA) concentrations of 9 patients decreased after carbapenem was started. The serum VPA concentrations of patients 3, 4, and 7 increased after
carbapenem was discontinued.
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Valproic acid, an anticonvulsant, is commonly used to treat
various forms of epilepsy. The main metabolic pathways of VPA
include N-glucuronidation, mitochondrial b-oxidation and cyto-
chrome P-450 (CYP) microsomal oxidation [20]. CYP isoenzyme-
inducing drugs such as phenytoin, carbamazepine, and phenobar-
bital decrease serum VPA concentrations [21]. Since 1997, several
case reports have been published indicating marked reductions
in serum VPA concentrations and, in some cases, breakthrough
seizures, during concomitant VPA and carbapenem treatment
(Table 1) [2e17,19]. In these reports, VPA concentrations fell withinabout 1 to 7 days of initiation of carbapenem therapy and recovered
completely within 3 days to 2 weeks after discontinuation of car-
bapenem. Additionally, results of a retrospective study of 36 patients
revealed that the mean serum VPA concentration decreased from
50.8  4.5 mg/mL to 9.9  2.1 mg/mL following meropenem admin-
istration, remained low for 7 days, and then gradually increased 8
to 14 days after discontinuation of meropenem, reaching values
comparable to those before initiation of meropenem [16]. The
pattern of a reduced VPA concentration during concomitant carba-
penem treatment was similar between our patients and previous
reports, suggesting that the interaction between VPA and carbape-
nem antibiotics is a class effect.
M.-C. Lee et al. / Tzu Chi Medical Journal 24 (2012) 80e84 83The mechanism of the interaction between carbapenems and
VPA has been explored in several animal studies but has yet to be
fully elucidated. Possible mechanisms include interference with
VPAmetabolism, alterations in the intestinal absorption of VPA, and
a shift in the distribution of VPA (Table 3) [22]. From an enzymatic
interference perspective, Yokogawa et al indicated thatmeropenem
accelerated the glucuronidation of VPA to VPA glucuronide (VPA-G),
and inhibited the hydrolysis (deconjugation) of VPA-G back to the
parent compound, thus increasing the clearance of VPA and VPA-G
[23]. Yamamura et al examined the interaction between panipenem
and valproic acid in rats. They showed that panipenem signiﬁcantly
increased hepatic uridine diphosphate (UDP)-glucuronic acid levels
by about 1.7-fold (p < 0.05) along with an increase in VPA-
glucuronide formation. Furthermore, this study also indicated
that panipenem does not cause enzyme induction or allosteric
activation of UDP-glucuronosyltransferases, enzymes responsible
for the glucuronidation of VPA, but most likely increases UDP-
glucuronic acid levels [24]. However, Nakajima et al found no
correlation between glucuronidation acceleration and the levels of
UDP-glucuronic acid in monkeys and rats, and suggested that car-
bapenem antibiotics greatly inhibit the hydrolysis of valproic acid
glucuronide to valproic acid in the liver, and increase the clearance
of valproic acid glucuronide by hepatocytes and the kidneys [25].
Torii et al [26] conducted a study in rats to determine the effect
of imipenem on serum VPA concentrations after administration of
oral VPA. The area under the serum concentration-time curve of the
orally administered VPA decreased by 57% (p < 0.01) after intra-
venous administration of imipenem. Utilizing in situ vascular and
luminal perfused small intestine, they found the absorption of VPA
from the luminal to the vascular perfusate was decreased in the
presence of imipenem. However, it is possible that imipenem also
inhibits the reabsorption of valproic acid during enterohepatic
recirculation. Torii et al [27] also reported that carbapenems may
inhibit valproic acid transport in Caco-2 cell monolayers. Valproic
acid absorption at the basolateral membrane of intestinal epithelial
cells was inhibited by carbapenems, resulting in a decrease in
serum VPA concentration after oral administration.
It has been suggested that the decrease in serum VPA concen-
trations with concomitant carbapenem treatment may be partly
due to an increase in erythrocyte distribution of valproic acid in rats
and humans [28]. Further, Ogawa et al [29] found that in the
presence of carbapenems, the efﬂux of valproic acid from eryth-
rocytes was inhibited by multidrug resistance-associated proteins
in rats.
Our results revealed that the onset of the interaction can be
rapid, as a signiﬁcant decrease in the serum VPA concentration
was observed within 1 to 9 days. This suggests that the mecha-
nism of the interaction may involve enzyme inhibition rather than
enzyme induction, because any enzymatic induction process
usually takes days to weeks to occur. Similar to previously pub-
lished results, our results revealed a slow recovery of serum VPATable 3
The possible mechanisms of the interaction between VPA and carbapenems.
Type Mechanism
Absorption The perfusion of VPA from the luminal to the vascular perfusate
was decreased. [26]
The absorption of VPA at the basolateral membrane of intestinal
epithelial cells was inhibited. [27]
Distribution Erythrocyte distribution of VPA was increased. [28]
The efﬂux of VPA from erythrocytes was inhibited by multidrug
resistant-associated proteins. [29]
Metabolism The glucuronidation of VPA to VPA-G was accelerated and the
hydrolysis of VPA glucuronide back to the parent compound
was inhibited. [23]concentrations after discontinuation of carbapenems, which is
longer than kinetically dictated by the carbapenem half-life.
Although there are no in vitro data to support this hypothesis,
we suggest that the inhibition of beta-glucuronidase by carbape-
nems could be irreversible; therefore, recovery of serum VPA
concentrations is dependent on the rate of the enzyme turnover
and not the carbapenem half-life.
Only one patient had seizures in this study. Possible reasonsmay
be that VPA was used for seizure prophylaxis in patients with brain
injuries, or that the patients were taking at least two antiepileptic
drugs to control seizures.
The interaction between VPA and carbapenems resulted in
decreased serum concentrations of VPA. The mechanism of this
interaction is unclear, however the rapid onset suggests enzymatic
inhibition is likely. Increasing the dose of VPA during concomitant
carbapenem therapy did not elevate the serum concentrations of
VPA. Clinicians should be aware of this potential interaction, and
closely monitor serum VPA concentrations and possible failure to
control seizures during the concomitant use of carbapenems.References
[1] Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy
in seizure emergency situations including status epilepticus-experience in
102 adult patients. Seizure 2005;14:164e9.
[2] Nagai K, Shimizu T, Togo A, Takeya M, Yokomizo Y, Sakata Y, et al. Decrease in
serum levels of valproic acid during treatment with a new carbapenem,
panipenem/betamipron. J Antimicrob Chemother 1997;39:295e6.
[3] De Turck BJ, Diltoer MW, Cornelis PJ, Maes V, Spapen HD, Camu F, et al.
Lowering of plasma valproic acid concentrations during concomitant therapy
with meropenem and amikacin. J Antimicrob Chemother 1998;42:563e4.
[4] Yamagata T, Momoi MY, Murai K, Ikematsu K, Suwa K, Sakamoto K, et al.
Panipenem-betamipron and decreases in serum valproic acid concentration.
Ther Drug Monit 1998;20:396e400.
[5] Llinares Tello F, Bosacoma Ros N, Hernandez Prats C, Climent Grana E, Selva
Otaolaurruchi J, Ordovas Baines JP. Pharmacokinetic interaction between
valproic acid and carbapenem-like antibiotics: a discussion of three cases.
Farm Hosp 2003;27:258e63.
[6] Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of val-
proic acid. Pediatr Neurol 2004;31:232e4.
[7] Clause D, Decleire PY, Vanbinst R, Soyer A, Hantson P. Pharmacokinetic
interaction between valproic acid and meropenem. Intensive Care Med 2005;
31:1293e4.
[8] Coves-Orts FJ, Borras-Blasco J, Navarro-Ruiz A, Murcia-Lopez A, Palacios-
Ortega F. Acute seizures due to a probable interaction between valproic acid
and meropenem. Ann Pharmacother 2005;39:533e7.
[9] Santucci M, Parmeggiani A, Riva R. Seizure worsening caused by decreased
serum valproate during meropenem therapy. J Child Neurol 2005;20:
456e7.
[10] Cabanes Mariscal MA, Sanchez Lopez P, Alvarez Herranz P, Chamorro
Merino G. Pharmacokinetic interaction between valproic acid and ertapenem.
Farm Hosp 2006;30:313e5.
[11] Fudio S, Carcas A, Pinana E, Ortega R. Epileptic seizures caused by low valproic
acid levels from an interaction with meropenem. J Clin Pharm Ther 2006;31:
393e6.
[12] Spriet I, Meersseman W, De Troy E, Wilmer A, Casteels M, Willems L. Mer-
openem-valproic acid interaction in patients with cefepime-associated status
epilepticus. Am J Health Syst Pharm 2007;64:54e8.
[13] Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving
divalproex sodium after starting ertapenem therapy. Pharmacotherapy 2007;
27:1202e5.
[14] Lee SG, Kim JH, Joo JY, Kwon OH. Seven cases of decreased serum valproic acid
concentration during concomitant use of carbapenem antibiotics. Korean J Lab
Med 2007;27:338e43.
[15] Gu J, Huang Y. Effect of concomitant administration of meropenem and val-
proic acid in an elderly Chinese patient. Am J Geriatr Pharmacother 2009;7:
26e33.
[16] Haroutiunian S, Ratz Y, Rabinovich B, Adam M, Hoffman A. Valproic acid
plasma concentration decreases in a dose-independent manner following
administration of meropenem: a retrospective study. J Clin Pharmacol 2009;
49:1363e9.
[17] Tobin JK, Golightly LK, Kick SD, Jones MA. Valproic acid-carbapenem inter-
action: report of six cases and a review of the literature. Drug Metabol Drug
Interact 2009;24:153e82.
[18] Liao FF, Huang YB, Chen CY. Decrease in serum valproic acid levels during
treatment with ertapenem. Am J Health Syst Pharm 2010;67:1260e4.
[19] Hellwig TR, Onisk ML, Chapman BA. Potential interaction between valproic
acid and doripenem. Curr Drug Saf 2011;6:54e8.
M.-C. Lee et al. / Tzu Chi Medical Journal 24 (2012) 80e8484[20] Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM. Metabolism and
excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol
1999;19:511e32.
[21] Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J
Clin Pharmacol 2006;61:246e55.
[22] Mancl EE, Gidal BE. The effect of carbapenem antibiotics on plasma concen-
trations of valproic acid. Ann Pharmacother 2009;43:2082e7.
[23] Yokogawa K, Iwashita S, Kubota A, Sasaki Y, Ishizaki J, Kawahara M, et al.
Effect of meropenem on disposition kinetics of valproate and its metabolites
in rabbits. Pharm Res 2001;18:1320e6.
[24] Yamamura N, Imura-Miyoshi K, Naganuma H. Panipenum, a carbapenem
antibiotic, increases the level of hepatic UDP-glucuronic acid in rats. Drug
Metab Dispos 2000;28:1484e6.
[25] Nakajima Y, Mizobuchi M, Nakamura M, Takagi H, Inagaki H, Kominami G,
et al. Mechanism of the drug interaction between valproic acid andcarbapenem antibiotics in monkeys and rats. Drug Metab Dispos 2004;32:
1383e91.
[26] Torii M, Takiguchi Y, Saito F, Izumi M, Yokota M. Inhibition by carbapenem
antibiotic imipenem of intestinal absorption of valproic acid in rats. J Pharm
Pharmacol 2001;53:823e9.
[27] Torii M, Takiguchi Y, Izumi M, Fukushima T, Yokota M. Carbapenem antibi-
otics inhibit valproic acid transport in Caco-2 cell monolayers. Int J Pharm
2002;233:253e6.
[28] Omoda K, Murakami T, Yumoto R, Nagai J, Maeda Y, Kiribayashi Y, et al.
Increased erythrocyte distribution of valproic acid in pharmacokinetic inter-
action with carbapenem antibiotics in rat and human. J Pharm Sci 2005;94:
1685e93.
[29] Ogawa K, Yumoto R, Hamada N, Nagai J, Takano M. Interaction of valproic acid
and carbapenem antibiotics with multidrug resistance-associated proteins in
rat erythrocyte membranes. Epilepsy Res 2006;71:76e87.
